Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial ☆
Titel:
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial ☆
Auteur:
Dent, S. Cortés, J. Im, Y.-H. Diéras, V. Harbeck, N. Krop, I.E. Wilson, T.R. Cui, N. Schimmoller, F. Hsu, J.Y. He, J. De Laurentiis, M. Sousa, S. Drullinsky, P. Jacot, W.